Streetbeat News

Analyst Ratings

NVDA

Goldman Sachs analyst Toshiya Hari maintains a Buy rating on NVIDIA and raises the price target from $440 to $495.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:45 pm

SWAV

Morgan Stanley analyst Patrick Wood has upgraded ShockWave Medical (NASDAQ:SWAV) from Equal-Weight to Overweight and raised the price target from $291 to $335.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:43 pm

NTRS

UBS analyst Brennan Hawken has downgraded Northern Trust (NASDAQ:NTRS) from Buy to Neutral and lowered the price target from $100 to $80.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:36 pm

JD

NVO

QQQ

SPY

TSLA

The U.S. consumer price index (CPI) inflation report for June is set to be released on Wednesday. Economists anticipate the annual U.S. headline inflation rate to drop from 4% to 3.1%, marking the 12th consecutive month of declines. The core CPI is expected to decline from 5.3% to 5%. The market remains uncertain about the possibility of two rate hikes this year. Previous CPI readings have impacted various stocks and ETFs.

Portfolio Pulse from Piero Cingari

July 10, 2023 | 1:36 pm

GEF

B of A Securities analyst George Staphos has upgraded Greif (NYSE:GEF) from Underperform to Neutral.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:34 pm

BCC

B of A Securities analyst George Staphos has upgraded Boise Cascade (NYSE:BCC) from Underperform to Neutral.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:34 pm

HOOD

JMP Securities analyst Devin Ryan has reiterated a Market Outperform rating on Robinhood Markets (NASDAQ:HOOD) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:32 pm

AAP

Advanced Auto Parts (AAP) shares are trading lower after Atlantic Equities downgraded the stock from Neutral to Underweight and lowered its price target from $130 to $50.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 1:31 pm

IBRX

ImmunityBio, Inc. (NASDAQ:IBRX) announced findings from a Phase 1 study indicating that allogeneic cytokine-induced memory-like (CIML) natural killer (NK) cells used in combination with ImmunityBio's IL-15 superagonist N-803 may induce tumor regression in advanced head-and-neck cancer patients. The study, sponsored by Dana-Farber Cancer Institute, showed that tumor regression was associated with expansion of the NK cell type with cytolytic activity. The results may have potential implications for many of the estimated 68,000 men and women in the United States who are diagnosed with head-and-neck cancers annually.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 1:31 pm

FRGE

JMP Securities analyst Devin Ryan has reiterated a Market Outperform rating on Forge Global Holdings (NYSE:FRGE) and maintained a $7 price target.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:06 pm